Publication Name	World Journal of Clinical Oncology
Manuscript ID	40835
Country	Italy

Received	2018-07-13 01:46
Peer-Review Started	2018-07-13 06:35
To Make the First Decision	2018-10-08 07:33
Return for Revision	2018-10-10 01:15
Revised	2018-10-16 12:43
Second Decision	2018-11-23 09:55
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2018-11-26 18:56
Articles in Press	2018-11-26 18:56
Publication Fee Transferred
Edit the Manuscript by Language Editor	2018-12-01 01:47
Typeset the Manuscript	2018-12-17 03:15
Publish the Manuscript Online	2018-12-21 01:32

ISSN	2218-4333 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Editorial
Article Title	Current status of PI3K-mTOR inhibition in hormone-receptor positive, HER2-negative breast cancer
Manuscript Source	Invited Manuscript
All Author List	Navid Sobhani, Daniele Generali, Fabrizio Zanconati, Marina Bortul and Bruna Scaggiante
ORCID	Author(s) ORCID Number Navid Sobhani http://orcid.org/0000-0003-1381-0283 Daniele Generali http://orcid.org/0000-0003-2480-3855 Fabrizio Zanconati http://orcid.org/0000-0001-5357-9579 Marina Bortul http://orcid.org/0000-0002-5107-9607 Bruna Scaggiante http://orcid.org/0000-0002-8662-138X
Funding Agency and Grant Number	Funding Agency Grant Number Beneficentia Stiftung BEN2016/16 Ricerca Sanitaria LILT 2015
Corresponding Author	Bruna Scaggiante, PhD, Professor, Department of Life Sciences, University of Trieste, Via Giorgeri, 1, Trieste 34127, Italy. bscaggiante@units.it
Key Words	Hormone receptor positive/Her2-negative breast cancer; PI3K; mTOR; TORC1/2; Akt; Everolimus
Core Tip	The phosphatidylinositol 3-kinase-mammalian target of rapamycin (PI3K-mTOR) pathway sustains cancer progression and drug resistance. The first Food and Drug Administration approved molecule against this pathway was everolimus, an mTOR inhibitor, to be used in combination with exemestane in HR+/HER2- breast cancers progressing to non-steroidal aromatase inhibitors. Drugs targeting other effectors such as PI3K, PI3K, Akt and mTORC1/2 have gained clinical interest. Nevertheless, everolimus remains the best option due to the relevant toxicity of the other drugs targeting the PI3K-mTOR pathway. Future directions are pointing to the development of biomarkers identifying those patients who would benefit from the PI3K-mTOR inhibitors for an improvement of their overall survival.
Publish Date	2018-12-21 01:32
Citation	Sobhani N, Generali D, Zanconati F, Bortul M, Scaggiante B. Current status of PI3K-mTOR inhibition in hormone-receptor positive, HER2-negative breast cancer. World J Clin Oncol 2018; 9(8): 172-179
URL	https://www.wjgnet.com/2218-4333/full/v9/i8/172.htm
DOI	https://dx.doi.org/10.5306/wjco.v9.i8.172

Full Article (PDF)	WJCO-9-172.pdf
Full Article (Word)	WJCO-9-172.doc
Manuscript File	40835-Review.docx
Answering Reviewers	40835-Answering reviewers.pdf
Audio Core Tip	40835-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	40835-Conflict-of-interest statement.pdf
Copyright License Agreement	40835-Copyright license agreement.pdf
Approved Grant Application Form(s) or Funding Agency Copy of any Approval Document(s)	40835-Grant application form(s).pdf
Non-Native Speakers of English Editing Certificate	40835-Language certificate.pdf
Peer-review Report	40835-Peer-review(s).pdf
Scientific Misconduct Check	40835-Scientific misconduct check.pdf
Scientific Editor Work List	40835-Scientific editor work list.pdf